Top

Supportive Care in Cancer

Published in:

01-08-2019 | Breast Cancer | Original Article

Cognitive effects of adjuvant endocrine therapy in older women treated for early-stage breast cancer: a 1-year longitudinal study

Authors: E. A. Underwood, K. J. Jerzak, G. Lebovic, P. A. Rochon, C. Elser, K. I. Pritchard, M. C. Tierney

Published in: Supportive Care in Cancer | Issue 8/2019

Abstract

Purpose

Evidence suggests endocrine therapy (ET) for breast cancer (BC) has adverse cognitive effects, but its specific effects on older women are unknown. This is despite the fact that older women are at increased risk of both breast cancer (BC) and cognitive decline relative to younger women. This study prospectively examined the cognitive effects of ET in a cohort of older BC patients. Our primary outcome measure was change in verbal memory, the cognitive domain most consistently affected by estrogen deprivation.

Methods

Forty-two chemotherapy-naïve women age 60+, without dementia and recently diagnosed with hormone receptor-positive BC, completed neuropsychological tests at the time of ET initiation and after 1 year of treatment. Change in age-standardized verbal memory performance was examined using paired t tests. To assess a broader range of potential cognitive effects, we also examined changes in visual memory, processing speed, frontal executive function, and perceptual reasoning.

Results

Participants exhibited significant decline from baseline to 1 year in verbal memory (p = 0.01). This decline was small to moderate in effect size (d = − 0.40). Performance on other domains did not change significantly over the year (all p > 0.05).

Conclusions

Our findings suggest potentially detrimental effects of ET on verbal memory in older women after just 1 year of treatment. Given that ET is prescribed for courses of 5 to 10 years, additional studies examining longer-term effects of treatment in older women are critical.

Available only for authorised users

Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ, Stearns V, Winer EP, Griggs JJ (2014) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline focused update. J Clin Oncol 32(21):2255–2269. https://doi.org/10.1200/jco.2013.54.2258 CrossRefPubMedPubMedCentral

J F IS, M E RD, S E CM, M R DMP, D F FB (2014) GLOBOCAN 2012 v1.1, Cancer incidence and mortality worldwide: IARC CancerBase no. 11 International Agency for Research on Cancer. http://globocan.iarc.fr

Anderson WF, Katki HA, Rosenberg PS (2011) Incidence of breast cancer in the United States: current and future trends. J Natl Cancer Inst 103(18):1397–1402. https://doi.org/10.1093/jnci/djr257 CrossRefPubMedPubMedCentral

Galea LAM, Frick KM, Hampson E, Sohrabji F, Choleris E (2017) Why estrogens matter for behavior and brain health. Neurosci Biobehav Rev 76:369–379. https://doi.org/10.1016/j.neubiorev.2016.03.024 CrossRef

Underwood EA, Rochon PA, Moineddin R, Lee PE, Wu W, Pritchard KI, Tierney MC (2017) Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis. Breast Cancer Res Treat 168:299–310. https://doi.org/10.1007/s10549-017-4627-4 CrossRefPubMed

Ahles TA, Root JC, Ryan EL (2012) Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol 30(30):3675–3686CrossRefPubMedPubMedCentral

Lange M, Rigal O, Clarisse B, Giffard B, Sevin E, Barillet M, Eustache F, Joly F (2014) Cognitive dysfunctions in elderly cancer patients: a new challenge for oncologists. Cancer Treat Rev 40(6):810–817CrossRefPubMed

Mandelblatt JS, Jacobsen PB, Ahles T (2014) Cognitive effects of cancer systemic therapy: implications for the care of older patients and survivors. J Clin Oncol 32(24):2617–2626. https://doi.org/10.1200/jco.2014.55.1259 CrossRefPubMedPubMedCentral

Lange M, Joly F (2017) How to identify and manage cognitive dysfunction after breast cancer treatment. J Oncol Pract 13(12):784–790. https://doi.org/10.1200/jop.2017.026286 CrossRefPubMed

10.

Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, Huizenga HM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB (2010) Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol 28(8):1294–1300CrossRefPubMed

11.

Phillips SM, Sherwin BB (1992) Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocr 17(5):485–495. https://doi.org/10.1016/0306-4530(92)90007-T CrossRef

12.

Epperson CN, Sammel MD, Freeman EW (2013) Menopause effects on verbal memory: findings from a longitudinal community cohort. J Clin Endocrinol Metab 98(9):3829–3838. https://doi.org/10.1210/jc.2013-1808 CrossRefPubMedPubMedCentral

13.

Zhou G, Liu J, Sun F, Duan L, Yan B, Peng Q (2011) Cognitive functioning in elderly women who underwent unilateral oophorectomy before menopause. Int J Neurosci 121(4):196–200. https://doi.org/10.3109/00207454.2010.542842 CrossRefPubMed

14.

American Joint Committee on Cancer (2006) Part IV: breast. In: Greene FL, Compton CC, Fritz AG, Shah JP, Winchester DP (eds) AJCC Cancer Staging Atlas. Springer, New York, pp 217–234

15.

Buschke H, Kuslansky G, Katz M, Stewart WF, Sliwinski MJ, Eckholdt HM, Lipton RB (1999) Screening for dementia with the memory impairment screen. Neurology 52(2):231. https://doi.org/10.1212/wnl.52.2.231 CrossRefPubMed

16.

Schmidt M (1996) Rey auditory verbal learning test: RAVLT : a handbook. Western Psychological Services, Los Angeles

17.

Geffen GM, Butterworth P, Geffen LB (1994) Test-retest reliability of a new form of the auditory verbal learning test. Arch Clin Neuropsychol 9(4):303–316CrossRefPubMed

18.

Benedict RHB, Schretlen D, Groninger L, Dobraski M, Shpritz B (1996) Revision of the brief visuospatial memory test: studies of normal performance, reliability, and validity. Psychol Assess 8(2):145–153CrossRef

19.

Reitan RM, Woflson D (1985) The halstead–reitan neuropsycholgical test battery: therapy and clinical interpretation. Neuropsychological Press, Tuscon, AZ

20.

Weschler D (2008) Weschler adult intelligence scale-iv. Pearson, New York

21.

Benton AL, Hamsher K, Sivan AB (1994) Multilingual aphasia examination. AJA Associates, Iowa City, IA

22.

Curran SL, Andrykowski JL, Studts JL (1995) Short form of the profile of mood states (poms–sf): psychometric information. Psychol Assess 7(1):80–83CrossRef

23.

Simon R, Latreille J, Matte C, Desjardins P, Bergeron E (2014) Adherence to adjuvant endocrine therapy in estrogen receptor–positive breast cancer patients with regular follow-up. Can J Surg 57(1):26–32. https://doi.org/10.1503/cjs.006211 CrossRefPubMedPubMedCentral

24.

Harrell FE (2015) Multivariable modeling strategies. In: Regression Modeling Strategies. Second edn. Springer, Cham, pp 53–85

25.

Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S (2009) Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study. Psycho-Oncology 18(8):811–821CrossRefPubMed

26.

Hedayati E, Alinaghizadeh H, Schedin A, Nyman H, Albertsson M (2012) Effects of adjuvant treatment on cognitive function in women with early breast cancer. Eur J Oncol Nurs 16(3):315–322CrossRefPubMed

27.

Debess J, Riis JO, Engebjerg MC, Ewertz M (2010) Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study. Breast Cancer Res Treat 121(1):91–100CrossRefPubMed

28.

Hurria A, Patel SK, Mortimer J, Luu T, Somlo G, Katheria V, Ramani R, Hansen K, Feng T, Chuang C, Geist CL, Silverman DH (2014) The effect of aromatase inhibition on the cognitive function of older patients with breast cancer. Clin Breast Cancer 14(2):132–140CrossRefPubMed

29.

Ganz PA, Petersen L, Castellon SA, Bower JE, Silverman DH, Cole SW, Irwin MR, Belin TR (2014) Cognitive function after the initiation of adjuvant endocrine therapy in early-stage breast cancer: an observational cohort study. J Clin Oncol 32(31):3559–3567CrossRefPubMedPubMedCentral

30.

Yesufu A, Bandelow S, Hogervorst E (2007) Meta-analyses of the effect of hormone treatment on cognitive function in postmenopausal women. Womens Health (Lond) 3(2):173–194. https://doi.org/10.2217/17455057.3.2.173 CrossRef

31.

LeBlanc ES, Janowsky J, Chan BK, Nelson HD (2001) Hormone replacement therapy and cognition: systematic review and meta-analysis. J Am Med Assoc 285(11):1489–1499CrossRef

32.

Wolf OT, Kirschbaum C (2002) Endogenous estradiol and testosterone levels are associated with cognitive performance in older women and men. Horm Behav 41(3):259–266. https://doi.org/10.1006/hbeh.2002.1770 CrossRefPubMed

33.

Hogervorst E, De Jager C, Budge M, Smith AD (2004) Serum levels of estradiol and testosterone and performance in different cognitive domains in healthy elderly men and women. Psychoneuroendocr 29(3):405–421CrossRef

34.

Drake EB, Henderson VW, Stanczyk FZ, McCleary CA, Brown WS, Smith CA, Rizzo AA, Murdock GA, Buckwalter JG (2000) Associations between circulating sex steroid hormones and cognition in normal elderly women. Neurology 54(3):599–603CrossRefPubMed

35.

Tierney MC, Moineddin R, McDowell I (2010) Prediction of all-cause dementia using neuropsychological tests within 10 and 5 years of diagnosis in a community-based sample. J Alzheimers Dis 22(4):1231–1240. https://doi.org/10.3233/jad-2010-100516 CrossRefPubMed

36.

Tierney MC, Yao C, Kiss A, McDowell I (2005) Neuropsychological tests accurately predict incident Alzheimer’s disease after five and ten years. Neurology 64:1853–1859CrossRefPubMed

37.

Rabin LA, Paré N, Saykin AJ, Brown MJ, Wishart HA, Flashman LA, Santulli RB (2009) Differential memory test sensitivity for diagnosing amnestic mild cognitive impairment and predicting conversion to Alzheimer’s disease. Neuropsychology, development, and cognition section B, aging, neuropsychology and cognition. 16(3):357–376. https://doi.org/10.1080/13825580902825220

38.

Andreotti C, Root JC, Schagen SB, McDonald BC, Saykin AJ, Atkinson TM, Li Y, Ahles TA (2016) Reliable change in neuropsychological assessment of breast cancer survivors. Psychooncology 25(1):43–50. https://doi.org/10.1002/pon.3799 CrossRefPubMed

39.

Phillips KA, Ribi K, Sun Z, Stephens A, Thompson A, Harvey V, Thurlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber RD, Bernhard J (2010) Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the big 1-98 randomized trial. Breast 19(5):388–395CrossRefPubMed

40.

Bender CM, Sereika SM, Brufsky AM, Ryan CM, Vogel VG, Rastogi P, Cohen SM, Casillo FE, Berga SL (2007) Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause 14(6):995–998. https://doi.org/10.1097/gme.0b013e318148b28b CrossRefPubMedPubMedCentral

Title: Cognitive effects of adjuvant endocrine therapy in older women treated for early-stage breast cancer: a 1-year longitudinal study
Authors: E. A. Underwood
K. J. Jerzak
G. Lebovic
P. A. Rochon
C. Elser
K. I. Pritchard
M. C. Tierney
Publication date: 01-08-2019
Publisher: Springer Berlin Heidelberg
Keywords: Breast Cancer
Breast Cancer
Estrogens
Published in: Supportive Care in Cancer / Issue 8/2019
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-018-4603-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2019

Eating-related distress in advanced cancer patients with cachexia and family members: a survey in palliative and supportive care settings

High concentration of topical amitriptyline for treating chemotherapy-induced neuropathies

Spirituality in cancer survivorship with First Nations people in Canada

Strategies of complementary and integrative therapies in cancer-related pain—attaining exhaustive cancer pain management

Integrative medicine therapeutic approaches to cancer care: patient preferences from focus groups

The nature of nausea: prevalence, etiology, and treatment in patients with advanced cancer not receiving antineoplastic treatment

Keynote webinar | Spotlight on antibody–drug conjugates in cancer